ImmunityBio, Inc. Common Stock (IBRX) is a publicly traded Healthcare sector company. As of July 6, 2026, IBRX trades at $9.49 with a market cap of $9.89B and a P/E ratio of -11.11. IBRX moved +0.00% today. Year to date, IBRX is +376.77%; over the trailing twelve months it is +257.58%. Its 52-week range spans $1.83 to $12.43. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces IBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IBRX Shares Fall After Insider Sale Following 2.61% Intraday Rally: IBRX shares rose 2.61% during regular trading but slipped overnight after an insider sold shares, testing retail optimism ahead of its lead drug’s upcoming FDA review. The insider sale marks the first such transaction this quarter as investors await the decision.
| Metric | Value |
|---|---|
| Price | $9.49 |
| Market Cap | $9.89B |
| P/E Ratio | -11.11 |
| EPS | $-0.85 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.43 |
| 52-Week Low | $1.83 |
| Volume | 8.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $140.98M |
| Net Income | $-854.60M |
| Gross Margin | 99.34% |
3 analysts cover IBRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.